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sonal (P = 0.0034), and output demand (P = 0.0174) subscales.
For the 150-mg group, the reduction in WLQ total index score
approached signiﬁcance (−2.9 [0.9]; P = 0.0545) and the mental-
interpersonal improved signiﬁcantly compared with placebo (P
= 0.0057). CONCLUSION: Reductions in hot ﬂush frequency
and severity and improved sleep and mood are accompanied by
signiﬁcant improvement in work productivity in postmenopausal
women treated with DVS.
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ECONOMIC EVALUATION OF FEMALE VACCINATION WITH A
QUADRIVALENT HUMAN PAPILLOMAVIRUS VACCINE IN
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OBJECTIVES: To evaluate the cost-effectiveness and budget
impact of vaccinating a single birth cohort of girls 11 years of
age with Gardasil, a novel vaccine against human papilloma
virus (HPV), in the presence of the current triennial cervical
screening programme. METHODS: A lifetime Markov model of
the incidence and prevalence of cervical dysplasia and cancer was
constructed from New Zealand cervical cancer registrations and
ﬁve-year survival plus the incidence of dysplasia estimated from
analyses of screening histories of 28,000 women. Costs of dys-
plasia, cervical cancer and genital warts were obtained from local
sources and health state utilities were taken from published
sources. Efﬁcacy was taken from several recent phase III clinical
trials (FUTURE). The model was internally validated against the
prevalence of dysplasia. RESULTS: Assuming lifetime protection
and 79% uptake of 3 doses, HPV vaccination would prevent 140
cervical cancer cases and 42 deaths over the lifetime of the vac-
cinated cohort. At a unit vaccine price per dose of $NZ128.50
and 5% annual discount rate, the cost per QALY in the base case
analysis is less than $NZ25,000 from either a health care or a
Government perspective. The annual budget impact of vaccina-
tion for the Government is $NZ10.5M. Catch-up vaccination
strategies for women age 12 to 26 y are more cost effective. These
ﬁndings are sensitive to the reduction in quality of life that
accompanies abnormal cytology or histology ﬁndings; vaccine
efﬁcacy; HPV genotype distribution; vaccine uptake and 
duration of protection. CONCLUSION: When a universal 
programme of HPV vaccination is added to current clinical
screening and management of dysplasia and cervical cancer, over
the lifetime of a birth cohort the cost required to provide each
additional quality adjusted life year is very modest by interna-
tional standards.
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MEDICATION COMPLIANCE TO STATIN THERAPY AND ITS
IMPACT ON DISEASE OUTCOMES IN TYPE 2 DIABETES
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OBJECTIVES: To examine the incidence of statin initiation in
patients with type 2 diabetes, medication compliance rates for
both antidiabetic and statin therapies, and the impact of patient
medication behavior on disease outcomes. METHODS: The Cal-
ifornia Medicaid program (Medi-Cal) claims data collected
during the period of January 1995 to December 2004 was ana-
lyzed. A total of 4222 patients with type 2 diabetes were included
in the study. Medication compliance was measured using Pro-
portion of Days Covered (PDC) in each quarter of the study
period. Descriptive analyses were performed to: 1) examine ini-
tiation of statin therapy and its change over time; and 2) compare
long-term medication compliance to statin and to antidiabetic
agents. A marginal structural model was employed to examine
the impact of medication compliance to statin therapy on car-
diovascular events. The effects of compliance on hospitalization
and total medical costs were estimated by generalized estimating
equations (GEE). RESULTS: Statin therapy was initiated by
2.71% of diabetic patients in 1996, rising to 18.08% in 2003.
Medication compliance to statin therapy was high (PDC = 0.83,
SD = 0.234) during the ﬁrst quarter of statin treatment. However,
patient compliance dropped sharply from the second quarter
(PDC = 0.63, SD = 0.382) and the medication compliance at the
end of the ﬁrst year of the treatment was decreased to 0.56. Over
the 30 quarters, patients were less likely to comply with statin
therapy than with antidiabetic treatment (approximately 35%
difference). Hispanic patients and patients with complicated
medication regimens were more likely to exhibit poor compli-
ance to statin therapy. Poor compliance to statin therapy was sig-
niﬁcantly associated with increased cardiovascular risk events (p
< 0.01) and hospitalization in patients with type 2 diabetes (p <
0.01). CONCLUSION: Prescribing of statins in diabetic popu-
lations has improved in recent years, but long-term medication
compliance to statin therapy and antidiabetic medications in the
California Medicaid population remains problematic.
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OBJECTIVES: To evaluate the impact of persistence with anti-
TNF treatment on rheumatoid arthritis (RA)-related health care
costs among RA patients. METHODS: A retrospective study, 
utilizing the PharMetrics managed-care claims database, was
conducted. The ﬁrst anti-TNF (inﬂiximab, etanercept, or adali-
mumab) plus methotrexate encounter among RA patients
between January 1, 2001 and January 1, 2004 was identiﬁed.
Patients were required to have a minimum of 12-months of con-
tinuous plan eligibility prior to and following their index bio-
logic date. Persistence (%) was deﬁned as the number of days
between their ﬁrst biologic prescription and the last biologic
encounter, divided by 365 and multiplied by 100. Two mutually
exclusive cohorts were developed based on their level of anti-
TNF persistence: individuals who were persistent ≥80%; and
those who were persistent <80%. RA-related costs were com-
pared between two groups. RESULTS: A total of 1242 patients
were included, 339 patients (27.3%) with a persistency ratio
<80% and 903 (72.7%) patients with a persistency ratio ≥80%.
Over two-thirds of the patients were females and the mean age
was 50 years. Other than pharmacy cost, higher persistence
resulted in lower non-pharmacy medical costs ($3091 versus
$4601). The higher persistence cohort had signiﬁcantly lower
cost in all non-pharmacy cost categories: inpatient services,
physician services, other out-patient services, emergency room,
and lab costs as compared to the lower persistence cohort. After
adjusting for confounding variables (age, gender, co-morbidity,
and disease staging), patients in the higher persistence group 
had a signiﬁcant lower non-pharmacy cost with a lower co-
morbidity. There was no difference in age, gender, and disease
staging between the groups. CONCLUSION: This study indi-
cates that while higher pharmacy costs were associated with
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higher persistence, non-prescription medical costs were reduced
for patients who were more persistent with anti-TNFs. Future
analyses need to examine the inﬂuence of higher persistence on
clinical outcomes.
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OBJECTIVE: This study investigated the relationship between
persistence with antihypertensive drugs (AHT) and blood pres-
sure (BP) goal attainment in clinical practice. METHODS: From
the PHARMO record linkage system comprising, among others,
linked drug-dispensing and hospital records of >2 million inhab-
itants in The Netherlands, new users of AHT were identiﬁed in
the period 1999–2004. Patients with stage 1 hypertension (sys-
tolic BP of 140–159 mmHg and/or diastolic BP of 90–99 mmHg)
or stage 2 hypertension (systolic BP ≥160 and/or diastolic BP ≥
100 mmHg) in the period of 6 months before onset of AHT treat-
ment were included in the study. Only patients with a BP mea-
surement in the period of 6–12 months after treatment onset
were included in the ﬁnal study cohort. Persistence with AHT
was determined by summing the number of days of continuous
treatment (gaps between dispensings <30 days) from treatment
onset. The outcome of interest was the ﬁrst BP measurement in
the period of 6–12 months after start. Patients with a BP below
140/90 mmHg were deﬁned “at goal”. RESULTS: The study
included 1271 patients of whom 1103 (87%) had stage 2 hyper-
tension. About 36% of patients with stage 1 and 13% of patients
with stage 2 hypertension were at goal at the time of the ﬁrst BP
measurement in the period of 6–12 months after treatment onset.
Fifty-four percent of patients with stage 1 hypertension and 73%
of patients with stage 2 hypertension were persistent with AHT
at goal attainment. Persistent use of AHT was associated with a
1.7 times increased chance of BP goal attainment in stage 2
hypertensive patients (RRadj = 1.67; 95%CI: 1.13–2.46), but
not in stage 1 hypertensive patients (RRadj = 1.04; 95%CI:
0.69–1.58). CONCLUSION: Persistent use of AHT plays an
important role in BP goal attainment in clinical practice in stage
2 hypertensive patients.
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OBJECTIVES: To investigate the association between the level of
adherence to GPAs and the risk of serious NSAID-related UGI
complications in patients using non-selective NSAIDs (nsN-
SAIDS). METHODS: A population based nested case-control
study was conducted within a cohort of new NSAID users with
at least one risk factor for a NSAID-related UGI complication
identiﬁed in the Dutch Integrated Primary Care Information data-
base between 1996–2005. Adherence to GPAs was calculated as
the proportion of NSAID treatment days covered (PDC) by a GPA
prescription. Multivariate conditional logistic regression analysis
was used to calculate adjusted odds ratios (OR) with 95% 
conﬁdence intervals (95%CI). RESULTS: Considering the most
recent episode of continuous nsNSAID use prior to the index date,
14.9% of the nsNSAID users received GPAs. Of these, 71.0%
had a PDC ratio >80% (full adherence), 22.0% PDC ratios
between 20–80% (partial adherence) and 7.0% being non-
adherent (PDC < 20%). The risk of a serious NSAID-related UGI
complication increased from 2.5 (95%CI: 1.0–6.7) in partially
adherent persons to 4.0 (95%CI: 1.2–13.0) in those with a PDC
< 20%. Considering the PDC level as a continuous measure, the
risk of a serious NSAID-related UGI complication increased with
16% (95%CI: 2–32%) with every 10% decrease in adherence.
Excluding H2RA users that were not adequately dosed for the
prevention of NSAID-related UGI complications; the risk was
increased 2.7-fold in patients that were partially adherent and
4.5-fold in patients that were non-adherent. CONCLUSION:
There is a strong relationship between the level of adherence to
gastroprotective medication and the risk of serious UGI compli-
cations in high-risk nsNSAID users. This underlines the need for
adequate patient instruction regarding adherence to GPAs and/or
the further development of ﬁxed combination strategies.
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OBJECTIVES: To compare results of alternative calibration
methods using a global model of human papillomavirus and cer-
vical cancer, adapted to the US setting. METHODS: We devel-
oped a mathematical model incorporating a Markov process
simulating six-month transitions between health states of HPV-
related cervical disease. We calibrated the model to primary 
endpoints, such as age-speciﬁc cervical cancer incidence and
mortality, and further used mathematical algorithms to ensure
model ﬁts to age-speciﬁc prevalence of cervical intraepithelial
lesions (CIN, grades 1–3). Calibration parameters consisted of
age- and HPV type-speciﬁc transition probabilities, and data on
US calibration targets and ranges for transition probabilities
were obtained through an extensive review of the published lit-
erature. Three methods of calibration were sequentially used to
calibrate the model: manual, random computer search, and
Nelder-Mead computer optimization algorithm. Maximum like-
lihood estimation and weighted mean percentage deviation were
used to evaluate the goodness-of-ﬁt of each calibration, alter-
nately. All calibration strategies were compared using percentage
difference from the optimal goodness-of-ﬁt score. RESULTS: The
uncalibrated model deviated from the optimal ﬁt by 62%, the
manual calibration by 20%, the random search by 13%, and 
the Nelder-Mead optimization by 10% when using maximum
likelihood as the goodness-of-ﬁt criteria. When using weighted
mean percentage deviation as the goodness-of-ﬁt criteria, the 
corresponding percentages were 39% (uncalibrated), 19%
(manual), 15% (random), and 11% (Nelder-Mead). Using
weighted mean percentage deviation, when compared to
maximum likelihood, as the goodness-of-ﬁt criteria resulted in 
a closer ﬁt to primary model endpoints, including cervical 
cancer incidence and mortality. CONCLUSION: Computerized
methods of model calibration such as the Nelder-Mead opti-
mization algorithm can substantially improve the predictive
validity of a pharmacoeconomic model. Careful selection of the
goodness-of-ﬁt criteria is necessary to ensure that the model is
calibrated according to research needs.
